Fezolinetant
一、 Product Overview
Fezolinetant is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.It was approved by the US Food and Drug Administration (FDA) on May.12, 2023
二、Main products
Description | Structural Formula | CAS No. | Category |
Fezolinetant |
| 1629229-37-3 | API |
(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one |
| 1383146-20-0 | intermediates |
tert-butyl (R)-2-methyl-3-oxopiperazine-1-carboxylate |
| 1629229-82-8 | intermediates |
3-methyl-1,2,4-thiadiazole-5-carbohydrazide |
| 1375066-73-1 | intermediates |
4-fluorobenzoic acid |
| 456-22-4 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.